Multiple Myeloma News
Our physicians are frequently featured in patient education series. They present at major medical meetings, and publish extensively in peer-reviewed journals. This section includes links to some of these informative presentations and journal articles
Abstracts
American Association for Cancer Research, Annual Meeting 2024
American Society of Hematology (ASH), Annual Meeting 2023
- Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma
- Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients
- Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease
- Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial
- Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy
- Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma
- Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients – a Single-Center Observational Study
- Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma
- Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation
- Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
American Society of Hematology (ASH), Annual Meeting 2020
- CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
- Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
- A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
- CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, in Combination with Ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis Patients: Update of MANIFEST Phase 2 Study
- Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
- Identification of Potent Human Hematopoietic Stem Cells (HSCs) Using Mitochondrial Profile Towards Improving HSC Transplantation
- REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat
- PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients
- Mild Anemia As a Single Independent Predictor of Mortality in Patients with COVID-19
- Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy
- Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial
- Patient Similarity Network of Multiple Myeloma Identifies Patient Subgroups with Distinct Genetic and Clinical Features
- Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients
- 28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma
- Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab
- Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone
- Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
- Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis
- Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study
- Prevalence of Unexplained Erythrocytosis and Thrombocytosis - an Nhanes Analysis
- An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib
- Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)
- Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model
- Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry
American Society of Clinical Oncology, Annual Meeting 2020
- KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
- Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
- Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.
- Adverse event and outcome patterns in patients with advanced multiple myeloma in the United States.
- ISS stage and network risk score to predict benefits of multiple myeloma treatment options.
American Society of Hematology (ASH), Annual Meeting 2018
- Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma
- E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients
- MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1
- Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma
- Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study
- Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry
- Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
- Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)
- Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM
- Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis
American Society of Clinical Oncology, Annual Meeting 2018
- Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry
- Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM)
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study
- Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO)
- Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001
- Risk stratification of smoldering multiple myeloma (SMM): Predictive value of free light chains and group-based trajectory modeling (GBTM)
- Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry
- A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM)
- A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
- Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
American Society of Hematology (ASH), Annual Meeting 2017
- MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA
- Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine
- Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model
- Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project
- Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
- Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma
- Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
- Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect® MMpatient Registry
- Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database
- Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
- Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
- Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience
American Society of Clinical Oncology, Annual Meeting 2017
- Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.
- Risk stratification of smoldering multiple myeloma (SMM): Predictive value of free light chains and group-based trajectory modeling (GBTM).
American Society of Hematology (ASH), Annual Meeting 2016
- MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins
- Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
- Mutation Burden in Multiple Myeloma Is Captured by Gene Expression Profiles
- A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification
Press Releases
-
Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation
November 2, 2023 -
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
September 29, 2023 -
Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials
December 12, 2022 - Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
November 04, 2022 - Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients
September 01, 2022 - Mount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
June 16, 2022 - Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma
April 06, 2022 - Model May Better Classify Multiple Myeloma and Relapse Risks
January 17, 2022 - Mount Sinai Researchers Present Encouraging Clinical Trial Results on Novel Therapy for Bone Marrow Cance
December 11, 2021 - Potentially Serious Side Effect Seen in Patient after Immunotherapy
December 10, 2021 - Scientists Identify New Types of a Blood Cancer and Potential Targeted Treatments
November 17, 2021 - Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients
June 28, 2021 - Researchers Identify Potential Formula for Blood Cancer Vaccine
December 19, 2019 - Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
August 22, 2019 - Mount Sinai Researchers Create RNA and DNA-Sequencing Platform to Match Broader Swath of Cancer Drugs to Patients With Few Options
August 08, 2018 - New Therapeutic Target in Myeloma Discovered
March 7, 2016
Publications
- Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes
Blood Cancer Discovery. 2024 Sep 16. PMID: 39283238 - Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Nature Cancer. 2024 Aug 26. PMID: 39187595 - Linvoseltamab for treatment of relapsed/refractory multiple myeloma
Journal of Clinical Oncology. 2024 Jun 16. PMID: 38879802 - Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma
Cell Reports Medicine. 2024 May 20. PMID: 38776911 - Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myelo
Journal for Immunotherapy of Cancer. 2024 Apr 12. PMID: 38609316 - Real-World utilization of radiation therapy in multiple myeloma: An analysis of the Connect MM Registry
Practical Radiation Oncology. 2024 Mar-Apr. PMID 37984714 - T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails!
British Journal of Haematology. 2024 Mar. PMID: 38111092 - Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data
Current Problems in Cancer. 2024 Mar 27. PMID: 38547609 - Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis
American Journal of Hematology. 2024 Mar 15. PMID: 38488702 - Optimizing the CAR T-cell therapy experience in multiple myeloma: Clinical pearls from an expert roundtable
Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1. PMID: 38369437 - Regression of smoldering myeloma with treatment of Gaucher disease
Blood Advances. 2024 Jan 29. PMID: 38285963 - Creating equitable and inclusive clinical trials for multiple myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan. PMID: 37783639 - Analytical assessment and validation of the ProteinSimple ELLA serum B-cell maturation antigen assay
Practical Laboratory Medicine. 2024 Jan. 3. PMID: 38283321 - Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma
EBioMedicine. 2023 Dec. PMID: 37995467 - Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
Clinical Lymphoma, Myeloma and Leukemia. 2023 Dec. PMID: 37743180 - IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Blood Cancer Discovery. 2023 Nov 1. PMID: 37769148 - Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Blood Advances. 2023 Sep 23. PMID: 37772981 - Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology. 2023 Jun. PMID: 37403937 - Trial designs and endpoints for immune therapies in multiple myeloma
American Journal of Hematology. 2023 Mar. PMID: 36200130 - Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
Blood Advances. 2023 Mar 28. PMID: 36018226 - Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Blood. 2023 Feb 1. PMID: 36327160 - Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy
Blood. 2022 Nov 3. PMID: 36327160 - High dimensional immune profiling of smoldering multiple myeloma distinguishes distinct tumor microenvironments
Clinical Lymphoma, Myeloma and Leukemia. 2022 Jul 16. PMID: 35945129 - Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients
Blood Advances. 2022 Aug 27. PMID: 36018226 - Signature predicts response to selinexor in multiple myeloma
JCO Precision Oncology. 2022 Jun 6. PMID: 3570479 - Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
Cancer Cell. 2022 Apr 6. PMID: 35390296 - Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens
Journal for Immunotherapy of Cancer. 2022 Feb. PMID: 35190376 - Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
Cancer Medicine. 2022 Jan. PMID: 34921527 - Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Nature Medicine. 2021 December. PMID: 34893771 - Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Science Advances. 2021 Nov 17. PMID: 34788103 - Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Cancer Cell. 2021 Oct 18. PMID: 34706273 - Bispecific Antibodies in Multiple Myeloma: Present and Future
Blood Cancer Discovery. 2021 Sep. PMID: 34661161 - Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
Cancer Cell. 2021 Jun 29. PMID: 34242572 - Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Lancet. 2021 Jun 24. PMID: 34175021 - KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal. 2021 Jun 18. PMID: 34145225 - Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology. 2021 Jun 1. PMID: 34062004 - Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica. 2021 Jun 1. PMID: 32354874 - Selinexor for the treatment of patients with previously treated multiple myeloma
Expert Review of Hematology. 2021 May 14. PMID: 33985401 - Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
Annals of Hematology. 2021 May 10. PMID: 33970288 - Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Cancer. 2021 Mar 18. PMID: 33735504 - The management of patients with difficult-to-treat multiple myeloma
Future Oncology. 2021 Mar 12. PMID: 33706558 - Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report
Journal of Medical Case Reports. 2021 Feb 19. PMID: 33608053 - Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2021 Feb 7. PMID: 33716054 - Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA
Future Oncology. 2021 Feb. PMID: 33522834 - A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Expert Reviews of Hematology. 2021 Jan. PMID: 33331794 - Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Blood. 2020 Dec 24. PMID: 33367546 - Bispecifics, trispecifics, and other novel immune treatments in myeloma
Hematology, American Society of Hematology, Education Program. 2020 Dec 4. PMID: 33275733 - Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma
Annals of Hematology. 2020 Oct 2. PMID: 33009581 - Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
British Journal of Haematology. 2020 Jul 30. - A tertiary center experience of multiple myeloma patients with COVID-19: lessons earned and the path forward
Journal of Hematology & Oncology. 2020 Jul 14. PMID: 32664919 - Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
Expert Review of Hematology. 2020 Mar 9. PMID: 32148109 - Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2
American Journal of Hematology. 2019 Dec 8. PMID: 31814152 - Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Clinical Cancer Research. 2019 Dec 19. PMID: 31857430 - Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
New England Journal of Medicine. 2019 Aug 22. PMID: 31422920 - SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents
Clinical Lymphoma, Myeloma & Leukemia. 2019 Sep. PMID: 31427259 - Daratumumab Plus Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Blood. 2019 May 21. PMID: 31113777 - Indatuximab Ravtansine (BT062) Monotherapy in Patients with Relapsed and/or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia 2019 Feb 21. PMID: 30930134 - Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis
Clinical Lymphoma, Myeloma & Leukemia. 2019 Jan 19. PMID: 30878315 - Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies
Cancer Journal 2019 Jan/Feb. PMID: 30694857 - Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2018 Nov. PMID: 30187199 - Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Blood Advances. 2018 Jul 10. PMID: 29986853 - Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity
Advances in Experimental Medicine and Biology. 2018. PMID: 30411265 - Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
Blood Advances. 2018 Jul 10. PMID: 2991494 - Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
JCO Precision Oncology. 2018 Aug 8. PMID: 30706044 - Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling
Blood Advances. 2018 Jun 26. PMID: 29945937 - Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat
Future Oncology. 2018 May 30. PMID: 29846095 - Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Leukemia & Lymphoma. 2018 Apr 4. PMID: 29616843 - Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
Clinical Lymphoma, Myeloma & Leukemia. 2018 Feb. PMID: 29395837 - The effect of novel therapies in high-molecular-risk multiple myeloma
Clinical Advances in Hematology & Oncology. 2017 Nov. PMID: 29200420 - Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia. 2017 Sep 19. PMID: 29054515 - Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Blood. 2017 Aug 24. PMID: 28637662 - Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents
Bone Marrow Transplant. 2017 Jul 24. PMID: 28737774 - Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
Leukemia. 2017 Jun 23. PMID: 28642592 - A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma
Cancer. 2016 Nov 15. PMID: 27433944 - Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
Leukemia & Lymphoma. 2016 Nov. PMID: 26943456 - A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma
British Journal of Haematology. 2016 Oct 7. PMID: 27714761 - A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
British Journal Haematology. 2016 Sept. PMID: 27196567 - Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
Expert Review of Hematology. 2016 Jul. PMID: 27291638 - Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Blood. 2016 May 26. PMID: 26932802 - Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma
Cancer Research. 2016 Mar 1. PMID: 2687384 - The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
Cancer Medicine. 2016 Mar. PMID: 26799254 - Pharmacokinetics and safety of elotuzumab combined with lenalidomide and Dexamethasone in Patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study
Clinical Lymphoma, Myeloma & Leukemia. 2016 Mar. PMID: 26795075 - Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Lancet Haematology. 2015 Dec. PMID: 26686406 - Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Expert Review of Hematology. 2016 Jan. PMID: 26558304 - Serum free light chain assessment early after stem cell transplantation as a prognostic factor in multiple myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2015 Sept. PMID: 26119495 - Asymptomatic monoclonal gammopathies
Clinical Lymphoma, Myeloma & Leukemia. 2014 Sept. PMID: 25486961 - Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens
American Journal of Hematology. 2014 Jun. PMID: 24616227 - Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies
Clinical Advances in Hematology & Oncology. 2013. PMID: 24518521 - Risk stratification in multiple myeloma, part 1: characterization of high-risk disease
Clinical Advances in Hematology & Oncology. 2013 Aug. PMID: 24518420